Metastasis is directly or indirectly responsible for the majority of cancer deaths. Anti-
metastasis treatment is thus the key to cure cancer. Recent development in nanomedicine …

In the 10 years that have passed since the Nobel prize-winning discovery of RNA
interference (RNAi), billions of dollars have been invested in the therapeutic application of …

DNAzyme‐based gene therapy holds immense prospects for effectively treating severe
diseases, yet is constrained with inefficient delivery and unconditional activation. Herein, we …

Although the overall cure rate of acute lymphoblastic leukemia (ALL) in children is about 80
percent, affected adults fare less well. This review considers recent advances in the …

Imatinib, a potent inhibitor of the oncogenic tyrosine kinase BCR–ABL, has shown
remarkable clinical activity in patients with chronic myelogenous leukaemia (CML) …

Cisplatin and other DNA-damaging chemotherapeutics are widely used to treat a broad
spectrum of malignancies. However, their application is limited by both intrinsic and …

Abstract Imatinib, a Bcr-Abl tyrosine kinase inhibitor, is a highly effective therapy for patients
with chronic myelogenous leukemia (CML). Despite durable responses in most chronic …

Chronic myeloid leukaemia (CML) is a myeloproliferative disorder arising in the
haemopoietic stem cell (HSC) compartment. This disease is characterised by a reciprocal t …

Imatinib mesylate (IM), a potent inhibitor of the BCR/ABL tyrosine kinase, has become
standard first-line therapy for patients with chronic myeloid leukemia (CML), but the …

In recent years, the lymphocyte-specific protein tyrosine kinase (Lck) has emerged as one of
the key molecules regulating T-cell functions. Studies using Lck knock-out mice or Lck …